Objective: Preoperative or intraoperative risk assessment models are used to stratify patients with endometrial carcinoma to lymphadenectomy. Our aim was to determine whether preoperative analysis of L1 cell adhesion molecule (L1CAM) can improve risk assessment. Methods: Immunohistochemical L1CAM staining was performed on endometrial biopsies of 241 patients and paired hysterectomy samples of 75 patients. Risk assessment models based on preoperative histologic type and grade, myometrial invasion, and/or tumor diameter and alternative models incorporating preoperative L1CAM were compared with regard to their capability of predicting lymph nodal or distant metastasis. Soluble L1 levels were measured by enzyme-linked immunosorbent assay in serum samples of 40 patients with endometrial carcinoma. Results: The concordance rate between L1CAM staining results of preoperative and hysterectomy samples was moderate (J = 0.586, P G 0.0001). Preoperative L1CAM expression was associated with nonendometrioid histology, lymph node involvement, advanced stage, and positive peritoneal cytology. Receiver operating characteristic curve analyses showed that L1CAM did not significantly improve risk stratification algorithms based on traditional risk factors. Intraoperative tumor diameter was an effective surrogate for myometrial invasion. There was no statistical difference between L1 serum levels of patients with an L1CAM-positive or L1CAM-negative endometrial carcinoma (P = 0.786). Conclusions: L1 cell adhesion molecule expression in endometrial biopsy correlates with high-risk features of endometrial carcinoma but does not significantly improve risk stratification algorithms based on traditional factors. Soluble L1 detected in the serum of patients with endometrial carcinoma does not correlate with tumoral L1CAM expression.
preoperatively or intraoperatively based on features of the primary tumor, including histologic type, grade of differentiation, and depth of myometrial invasion (MI), as evaluated by preoperative histology, frozen-section analysis, and imaging.
The most validated algorithm (so-called Mayo criteria 3 ) defines low-risk endometrial carcinoma as endometrioid G1YG2 carcinoma with tumor diameter (TD) of 2 cm or less and MI of 50% or less. When this algorithm is applied, approximately 30% of the patients fall into the category of low risk for lymphatic dissemination and may avoid lymphadenectomy. 4, 5 The remaining 70% of the patients should undergo lymphadenectomy, yet only 19% to 22% of them present with lymph node metastases. 4, 5 More recently, a risk stratification model was presented, according to which more than 40% of the patients could be spared lymphadenectomy with a false-positive rate of 57.2% and false-negative rate of 0%. 6 This model is based on tumor grade (G1YG2 vs G3), diameter (50-mm cutoff ), and depth of MI (3-tiered). A major difficulty related to these algorithms is the often inaccurate assessment of MI by preoperative imaging or gross visualization. 7Y9 Frozen-section diagnosis is not readily available in many institutions, 10 and various investigators question its accuracy. 11Y13 Intraoperatively assessed TD has been proposed as a surrogate for MI. 6, 14, 15 Current risk assessment algorithms are burdened with a high frequency of presumably unnecessary lymphadenectomies. To overcome this problem, attention has been paid to the potential value of molecular markers (such as estrogen receptor/ progesterone receptor status in predicting lymph node involvement 16 ). Nevertheless, molecular markers do not have an established role in this setting, nor have they been integrated in randomized clinical trials of surgical therapies.
A promising prognostic marker, L1 cell adhesion molecule (L1CAM, CD171) predicts disease progression and poor prognosis in many types of cancer including endometrial carcinoma. 17Y23 The association between L1CAM expression and lymph node involvement of endometrial carcinoma suggests that L1CAM could be a useful biomarker for stratifying patients to lymphadenectomy. 21Y23 Also, a soluble form of L1CAM (sL1) exists and has been detected in the serum and ascites of patients carrying a tumor expressing this antigen.
17,24Y26
Based on the association of L1CAM expression with lymphatic dissemination in endometrial carcinoma, we wanted to evaluate the power of L1CAM in algorithms aimed at stratifying patients to lymph node dissection. To further clarify the potentiality of L1CAM as a biomarker, we compared serum L1CAM concentrations in patients with negative and positive L1CAM expression in tumor sections.
MATERIALS AND METHODS
Patients who underwent primary surgical treatment for endometrial carcinoma at the Department of Obstetrics and Gynecology, Helsinki University Hospital, between January 1, 2007, and December 31, 2009 , were identified. Patients with a preoperative endometrial sample available for L1CAM analysis were included in the study (n = 241). Approvals of the institutional review board and the National Authority for Medicolegal Affairs of Finland were obtained. During 2007Y2009, according to the treatment guidelines of our hospital, bilateral pelvic lymphadenectomy was performed in patients with grade 1 to 2 endometrioid carcinoma with less than 50% MI, the depth of invasion being assessed by vaginal ultrasound and gross visual inspection. In other patients, both pelvic and para-aortic lymphadenectomies were performed. There was some variation in practice patterns because the decision to perform lymphadenectomy and the extent of the procedure depended on patient age and surgical risks. Total rate of lymphadenectomy was 79.7%. Pertinent patient characteristics and surgical data are shown in Table 1 Tumor size was measured intraoperatively by the surgeon or after formaldehyde fixation by the pathologist. Primary TD was defined as the largest dimension of the tumor. If more than 1 lesion was present, the lesion with the largest diameter was considered. Primary TD was unknown in 14 patients. The presence of cervical stromal invasion was unknown in 2 patients. Peritoneal cytology was considered positive if carcinoma cells were detected in the peritoneal washing, regardless of the number of cancer cells. One case that was positive because of a concomitant borderline serous ovarian tumor was considered negative for endometrial cancer. Peritoneal cytology status was unknown in 4 patients. Preoperative L1CAM staining was assessed in tissue samples obtained by uterine aspiration biopsy or curettage. Uterine biopsy was the primary (990%) sampling method. Uterine curettage was performed when biopsy was insufficient for diagnosis or failed because of cervical stenosis. For immunohistochemical stainings, slides were stained with Ventana Benchmark XT automated slide preparation system (Ventana Medical Systems, Inc) or with Autostainer LV1 (Lab Vision Corporation). Briefly, slides were deparaffinized, and heat-induced epitope retrieval was performed following standard protocol. Tissue sections were incubated with primary monoclonal antibodies against L1CAM (CD171; clone 14.10, catalog no. SIG-3911-1000; Covance Inc, Princeton, NJ). The antibody binding site was visualized using a DAB detection kit. Sections were counterstained with Mayer hematoxylin, dehydrated, cleared in xylene, and mounted. L1 cell adhesion molecule positivity was defined as greater than 10% of the carcinoma cells staining in 1 representative slide evaluated by a pathologist ( Supplementary Fig. 1 , http://links. lww.com/IGC/A505). Neural cells of an appendix slide served as an external positive control, and myometrial nerves served as an internal positive control (for whole sections). For concordance studies, we stained the corresponding hysterectomy sections of all the patients with a positive (n = 50) and of 25 patients with a negative preoperative sample.
Starting from November 2014, we have obtained a preoperative blood sample from voluntary patients with endometrial carcinoma treated at the Department of Obstetrics and Gynecology, Helsinki University Hospital. Blood fractionation was carried out by centrifugation for 10 minutes at 2000g, and the samples were stored at j70-C. The serum samples of all the patients with an immunohistochemically verified L1CAM-positive (n = 17) and 23 patients with an L1CAM-negative endometrial carcinoma were retrieved. To determine the serum level of L1CAM, we used a commercial enzyme-linked immunosorbent assay (ELISA) kit (catalog no. LS-F24209; LifeSpan Biosciences Inc, Seattle, WA). Standards, controls, and samples were processed for sandwich ELISA according to the manufacturer's instructions, and duplicate wells were run for each sample. Final serum dilution (1:2000) was chosen after running test reactions on serial dilutions. The absorbance at 450 nm was measured by an automatic ELISA reader (Multiskan EX; Thermo Fisher Scientific). Results were expressed in nanogram per milliliter according to the established standard curve. The limit of detection was 93.75 to 6000 pg/mL.
Continuous variables (sL1) were compared using the Mann-Whitney U test. Pearson W 2 analyses were used to compute odds ratios (ORs) along with 95% confidence intervals (CIs) for the associations between preoperative L1CAM staining and various risk parameters in the cohort. Multiple regression analysis was used to estimate the independent effect of selected risk parameters on either preoperative L1CAM staining or lymph node/distant metastasis (stage IIICYIV disease). Cohen J statistics were calculated to measure the agreement of preoperative L1CAM staining and tumor histology with corresponding postoperative findings. Based on J references outlined by Landis and Koch, 31 
Multivariable models were created to test the capability of preoperative L1CAM to predict lymph node and distant metastasis in conjunction with other risk parameters. The estimated weight of each parameter included in a risk model was determined by rounding statistically significant ORs in the multivariable models to the nearest integer. These risk points of each factor were summed to generate a risk score potentially predicting the probability of advanced disease. The risk scores were used to test the discriminating abilities of the risk models with the 2-tailed receiver operating characteristic curve area comparison test. Alternative models were created by eliminating selected variables from the models. Statistical significance was set at P G 0.05. Data were analyzed using IBM SPSS version 22 software (IBM Corp, Armonk, NY).
RESULTS
Of the 241 preoperative endometrial samples, 64 (26.6%) were L1CAM positive. L1 cell adhesion molecule expression was observed in 22.3% (43/193) of grade 1 to 2 endometrioid carcinomas, 27.6% (8/29) of grade 3 endometrioid carcinomas, and 68.4% (13/19) of nonendometrioid carcinomas (P G 0.0001). According to J statistics in 75 sample pairs, preoperative L1CAM staining showed moderate agreement with findings in the whole section (J 0.586, P G 0.0001). By comparison, in the whole study population of 241 patients, J value was 0.551 (P G 0.0001) for the agreement of preoperative histology with final histology in detecting high-risk cases (grade 3 or nonendometrioid carcinoma). We did not observe any special L1CAM staining pattern, such as preferential positivity at the myoinvasive front, in the whole sections of hysterectomy specimens.
Preoperative L1CAM positivity was associated with disease spread beyond the uterine corpus, lymph node involvement, nonendometrioid histology, positive peritoneal cytology, and older age ( Table 2) . Logistic regression analysis indicated that nonendometrioid histology was independently associated with L1CAM positivity, whereas the effect of disease spread beyond uterine corpus, positive peritoneal cytology, or older age was not significant (Table 3) . Preoperative high-risk histology (grade 3 or nonendometrioid carcinoma), MI (933% or Q50%), TD (Q2 or Q5 cm), and preoperative L1CAM positivity were included in logistic regression models, with lymph node and distant metastasis as the dependent variable. Patients with available data for all the variables were included in each model (n Q 225). Tumor size 2 cm or greater was the only variable that failed to display a significant independent effect on the dependent variable ( Table 4) . Addition of L1CAM in the models did not significantly improve the areas under the curve (AUCs) of the risk stratification algorithms (P 9 0.28, Table 5 ). Elimination of MI from Cox Bauer model (TD Q5 cm, MI 933%) did not significantly diminish the AUC of the score (P = 0.429).
There was no statistically significant difference between the concentrations of soluble L1 (s-L1) in the serum samples of patients with L1CAM-positive or L1CAM-negative tumors (P = 0.786). The mean soluble L1 concentration was 3235.49 (SD, 808.60) ng/mL for L1CAM-positive cases and 3163.27 (SD, 765.90) ng/mL for L1CAM-negative cases. Median (25th and 75th percentiles) soluble L1 values were 3033.90 ng/mL (2680.60 and 3637.60 ng/mL, respectively) in patients with L1CAM-positive tumor and 2992.20 ng/mL (2649.75 and 3467.10 ng/mL, respectively) in L1CAM-negative control subjects.
DISCUSSION
Modern management of endometrial cancer is based on personalized surgical and adjuvant treatment. Reliable preoperative or intraoperative risk stratification plays a key role in tailoring optimal surgical treatment. Currently used risk assessment methods suffer from inaccuracy, and definite indications for lymphadenectomy are yet to be established.
L1 cell adhesion molecule is a promising prognostic marker that independently predicts poor outcome and lymph nodal involvement in endometrial carcinoma.
21Y23 Because L1CAM expression pattern is heterogeneous in endometrial carcinoma (10%Y100% of the carcinoma cells staining in a positive immunohistochemical assay), and endometrial aspiration biopsy represents only a small portion of the tumor, the true value of L1CAM as a preoperative marker has to be studied on preoperative diagnostic samples. Despite the heterogeneous staining pattern of L1CAM, we observed a moderate concordance rate (J = 0.586, P G 0.0001) between L1CAM staining in preoperative and hysterectomy samples. It is noteworthy that the concordance between preoperative and postoperative L1CAM staining was superior compared with the concordance of preoperative and postoperative histology (low vs high grade). L1 cell adhesion molecule expression was associated with disease spread beyond uterine corpus (OR = 2.5, P = 0.003), but its significant effect was lost once other factors were taken into account. Furthermore, L1CAM did not significantly improve the performance of risk assessment algorithms based on traditional risk factors. These results imply that L1CAM is not a useful tool for preoperative treatment planning of endometrial carcinoma.
Considering the common difficulties in assessing the depth of MI preoperatively, we wanted to test a model without MI as a parameter. Intraoperative TD is a more feasible measure because it can be reliably evaluated by gross inspection (by the surgeon) even when frozen-section analysis is not available. In our study cohort, the risk assessment model presented by Cox Bauer et al 6 performed equally well independently of the presence of MI as a parameter (AUC, 90.8; P = 0.429), suggesting that intraoperative TD could be used as an alternative to MI to identify high-risk disease, as indicated 17 detected sL1 in the blood of patients with an advanced L1CAM-positive ovarian or uterine carcinoma, but not in healthy subjects or patients with other types of tumors, suggesting that sL1 could be used in diagnostics or follow-up of ovarian and uterine carcinoma. Using a commercial ELISA kit optimized for serum samples, we were not able to confirm A strength of our study was its unselected cohort of patients with endometrial carcinoma treated at a single tertiary care center with well-defined diagnostic and operative standards and systematic follow-up procedures. The relatively high lymphadenectomy rate (192/241 [79.7%]) in the study cohort improved the diagnostics of occult nodal disease permitting more accurate staging. In our institution, frozen section is not used to determine the depth of MI, and data on MI had to be extrapolated from final pathological reports.
In summary, we found a moderate concordance for L1CAM status between endometrial biopsies and corresponding hysterectomy specimens. Preoperative L1CAM expression was associated with lymph nodal and distant metastasis, but L1CAM did not significantly improve risk stratification algorithms based on preoperative histology, TD, and/or MI. Interestingly, the performance of risk stratification models did not depend on the presence of MI as a variable, suggesting that the more feasible TD could be used as a surrogate variable. Based on our results, preoperative L1CAM cannot be recommended as a tool for stratifying patients with endometrial carcinoma to lymphadenectomy.
